WO2012120454A1 - Composition à base d'huile ozonisée destinée à une utilisation topique - Google Patents

Composition à base d'huile ozonisée destinée à une utilisation topique Download PDF

Info

Publication number
WO2012120454A1
WO2012120454A1 PCT/IB2012/051057 IB2012051057W WO2012120454A1 WO 2012120454 A1 WO2012120454 A1 WO 2012120454A1 IB 2012051057 W IB2012051057 W IB 2012051057W WO 2012120454 A1 WO2012120454 A1 WO 2012120454A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
composition
ozonized
composition according
ozonized oil
Prior art date
Application number
PCT/IB2012/051057
Other languages
English (en)
Inventor
Primo TORTINI
Alessia DE ASCENTIIS
Original Assignee
Neovalis S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovalis S.R.L. filed Critical Neovalis S.R.L.
Priority to BR112013022891A priority Critical patent/BR112013022891A2/pt
Priority to EP12717849.9A priority patent/EP2683356A1/fr
Priority to KR1020137026347A priority patent/KR20140071956A/ko
Priority to MA36296A priority patent/MA35021B1/fr
Priority to MX2013010275A priority patent/MX2013010275A/es
Publication of WO2012120454A1 publication Critical patent/WO2012120454A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations

Definitions

  • the present invention relates to a composition for topical use based on ozonized oil.
  • the invention relates to a sanitising medical device having topical activity that improves the process of regeneration of ulcers and of wounds, comprising ozonized oil for topical use.
  • the invention relates to a composition based on ozonized oil and its uses in the pharmaceutical and/or cosmetic sector.
  • the present invention specifically relates to a synergistic composition based on ozonized vegetable oil and a selected constituent, which composition is suitable for disinfecting epithelial-tissue lesions and restoring the physiological conditions of the damaged cutaneous and/or sub-cutaneous structures.
  • the skin is the most widespread tissue in the human organism and is known to perform numerous functions including that of protection from external agents.
  • the skin of the human organism can be damaged due both to external causes, such as in the case of lacerations, trauma, abrasions, skin burns, but also due to endogenous causes such as in the case of metabolic or ischemic diseases of peripheral type, wherein there is a reduction in the supply of oxygen and of nutrient substances. These pathological conditions lead to the formation of ulcers, sores and wounds, and to their becoming chronic.
  • the areas of the epidermis affected by wounds or ulcerations constitute a fertile terrain for the development of bacterial infections. Indeed, colonization by bacterial strains, in particular of Pseudomonas, ⁇ -hemolytic Streptococcus, Staphylococcus, Klebsiella and other pathogens in wounds and sores is frequently encountered.
  • Ozonized oils are the products of reacting unsaturated fatty acids with ozone (O 3 ), the triatomic form of oxygen.
  • compositions comprising combinations of ozonized oils with specific, likewise ozonized, natural or synthetic products, such as: vitamins, fatty acids having double bonds in position ⁇ -3, ⁇ -6, in a vehicle of pharmaceutical excipients and intended for cosmetic or pharmaceutical use, in particular for dermatological applications.
  • European patent application EP 2.149.598 further describes a method and a device for producing a vehicle or substrate for yielding ozone derivatives or ozonides that find applications as bactericidal medicinal products for the topical treatment of phlebitis, gangrene, thrombophlebitis, skin infections, including secondary-type determined by viral causes, and also for the treatment of inflammatory-infective diseases of the oral cavity, for promoting angioneogenesis, with the effect of regenerative action on the tissues.
  • US patent application US2009/0291122 defines ozonized vegetable oil as an oil that has been subjected to treatment with ozone gas until a variable ozone concentration in the oil from 15 to 53 mg of ozone per gram of oil is reached.
  • European patent application EP 1626767 describes a device adapted to providing a spray of ozonized water, usable for disinfecting and treating infected wounds, and illustrates the production and efficacy of relative oxygen species (ROS) which, in their "cascade" of rearrangement and transformation, co-assist the natural mechanisms of the organism in the removal of infections and inhibit the ' survival of anaerobic bacterial strains.
  • ROS relative oxygen species
  • ROS lipid peroxidation
  • LOPs lipid peroxidation
  • the Applicant has now found that by combining an ozonized oil with an essential oil extracted from chamomile, a synergistic bactericidal and cicatrising effect is obtained which is accompanied by a reduced formation of free radicals.
  • composition for topical use characterized in that it comprises an effective amount of at least one ozonized oil and an effective amount of an essential oil extracted from chamomile.
  • the essential oil usable within the scope of the invention may be extracted from flowers of the chamomile plant (Matricaria chamomilla) in accordance with conventional techniques, for example those reported in the Italian Pharmacopoeia.
  • the essential oil of chamomile may be obtained from heads of the plant by means of steam distillation.
  • the product obtained is typically a blue oil of viscous consistency.
  • said essential oil extracted from chamomile comprises or essentially consists of a-bisabolol.
  • the Applicant has furthermore unexpectedly found that combination of an ozonized oil with alpha-bisabolol determines a substantial reduction in the development of free radicals that is commonly observed for the ozonized oils in the ROS phase of release of ozonide ion radicals.
  • Alpha-bisabolol is a natural sesquiterpenic alcohol, also called levomenol, [23089-
  • Ci 5 H 26 of empirical formula Ci 5 H 26 0, which has a molecular weight of 222.37 and is designated (R)-6-methyl-2-((R)-4-methylcyclohex-3-enyl)ept-5-en-2-ol.
  • the ozonized oil used in the formulation of the composition of the invention is a reaction or addition product of ozone with one or more unsaturated fatty acids, for example those present in vegetable or synthetic fats or oils.
  • an oil of vegetable origin is used to obtain the ozonized oil.
  • suitable vegetable oils include, but are not limited to olive oil, sunflower oil, corn oil, mixed-seed oil, and mixtures thereof.
  • ozonized oils used within the scope of the invention may be obtained by means of conventional procedures and techniques.
  • suitable ozonized oils may be obtained with the procedure described in German patent
  • the ozonized oil used in the composition of the invention is based on a vegetable oil having an unsaturated fatty acid content of at least 80%.
  • the ozonized oils utilized within the scope of the invention are oils particularly rich in oleic and linoleic acid. These two fatty acids, subjected to ozonization, can typically produce addition with ozone up to a degree of peroxidation of at least 60% of unsaturations.
  • ROS rapid reaction with plasma
  • the present invention originates from the discovery that combination of an essential oil extracted from chamomile, in particular a-bisabolol, with an ozonized oil determines a synergy of antibacterial and/or cicatrising action on the damaged epidermis.
  • a composition for topical use comprising an effective amount of an ozonized oil in combination with an effective amount of an essential oil extracted from chamomile.
  • the ozonized oil present in the composition of the invention is obtained by ozonization of sunflower oil.
  • said essential oil extracted from chamomile or alpha-bisabolol is present in an amount within the range from 1 to 20%, preferably from 5 to 10% by weight, relative to said ozonized oil.
  • the ozonized oil present in the composition of the invention has a degree of peroxidation of up to 60% of the double bonds.
  • the ozonized oil of the composition of the invention has a peroxide index (PI) within the range from 3400 to 4600.
  • the oil ozonization is performed in a sealed reactor and under particular operating conditions.
  • a linear correlation was found between the peroxide index of the peroxidated oil and the density of the reaction medium. Said linear correlation proved exceedingly useful for controlling the reaction itself.
  • the ozonized oil derives from ozonization of a vegetable oil or from mixtures of various types of oil.
  • one formulation of the composition of the invention incorporates an ozonized sunflower oil the characteristics of which are listed, together with the characteristics of the sunflower oil starting substance, in Table I below.
  • Table I Characteristics of the ozonized oil having a peroxide index (PI) of approx. 4000 and its precursor sunflower oil.
  • the ozonized oil of the composition has a peroxide index (P I) equal to approximately 4000, corresponding to 96g of O3 (as a function of ozonide ion radical), and 64g of O 2 (as peroxide functions) per kg of product.
  • P I peroxide index
  • the a-bisabolol and the ozonized oil may be present in specific quantitative ratios.
  • the composition of the invention comprises ⁇ -bisabolol and ozonized oil in a ratio from 1 :5 to 1 :20.
  • One embodiment provides for an ⁇ -bisabolol and ozonized oil ratio of 1 :5 to 1 :10.
  • the composition of the invention comprises ⁇ -bisabolol and ozonized oil, respectively in a ratio of 1 to 10 parts.
  • composition of the invention may typically contain one or more additives and/or vehicles and/or excipients suitable for topical application in particular in the pharmaceutical or cosmetics sector, for human or veterinary use.
  • the composition of the invention may contain one or more substances selected from emollients, soothers, humectants, pH regulators, stabilizers, antimicrobials, substances that generate a protective skin, and one or more active principles of varied nature.
  • composition of the invention may comprise, as active principles, one or more micro-elements or trace elements, such as zinc, magnesium, selenium, manganese, in whatever form (salts, esters, hydroxides etc.) and a concentration that may vary, for example from 0.001 % to 10% by weight, relative to the weight of the total composition.
  • micro-elements or trace elements such as zinc, magnesium, selenium, manganese, in whatever form (salts, esters, hydroxides etc.) and a concentration that may vary, for example from 0.001 % to 10% by weight, relative to the weight of the total composition.
  • the composition may comprise vitamins, and/or their derivatives and/or precursors such as e.g. vitamins of group A, B, C, E, F, for example in a concentration that may vary from 0.001 to 25% by weight.
  • the composition of the invention may comprise substances, which play a role in the cicatrisation process of wounds, ulcers, skin sores, such as amino acids and derivatives thereof, such as cysteine, arginine, glycine, for example in quantities varying from 0.001 to 10%; fatty acids such as acids of type ⁇ -3 and/or ⁇ -6, linoleic or linolenic acid, in quantities which may vary for example from 0.001 to 30% by weight.
  • composition of the invention may further include one or more substances, which form protective coverings on the skin, such as perfluorocarbons, for example Fombolin®, in quantities varying from 0.001 to 10% by weight.
  • protective coverings on the skin such as perfluorocarbons, for example Fombolin®, in quantities varying from 0.001 to 10% by weight.
  • the two constituents of the composition, ozonized oil and alpha- bisabolol are present in an amount from 10% to 90% relative to the total weight of the formulation, the remainder to make up to 100% being composed of excipients or other substances, for example of the type previously described.
  • the composition of the invention is provided in liquid or semi-liquid form suitable for local application, for example as a gel or solution to be applied in the cutaneous zone in need of treatment.
  • the composition is provided in spray form.
  • the composition of the invention is provided in solid form, for example as a paste, pomade or cream.
  • composition of the invention is provided in the form of the device suitable for transdermal or cutaneous release of the active principles, for example, in the form of a transdermal patch.
  • composition of the invention finds applications in both the cosmetic and the pharmaceutical field.
  • composition of the invention finds applications in all cases wherein damage to the epidermal tissues occurs and wherein a sanitising treatment is required to restore the physiological conditions of the structures of the skin, and/or the damaged subcutaneous structures.
  • composition comprises ozonized oil, a-bisabolol in cosmetically advantageous quantities and a vehicle cosmetically advantageous for regeneration of the skin.
  • the composition for cosmetic use comprises one or more vehicles or excipients commonly used in the formulation of cosmetic preparations.
  • the composition of the invention is used for the cosmetic treatment of an non-aesthetic features of the skin, such as, for example, puckering, skin blemishes forming, in particular, with aging of the skin, vitiligo, wrinkles, stretch marks, or adiposity.
  • the present invention relates to a composition
  • a composition comprising ozonized oil and a-bisabolol in pharmaceutical advantageous quantities, for use in the treatment of a skin lesion.
  • skin lesion is used to mean any lesion of the epidermis wherein the epidermis is no longer intact or is lacerated or cut, or wherein there simply exists abrasion of the epidermis, even if only superficial.
  • Legions of the epidermis are, for example, wounds, skin sores, bed sores, ulcers and ulcerations, abrasions, burns.
  • the composition of the invention finds applications in the disinfection and/or cicatrisation of wounds, ulcers or skin sores. In accordance with another embodiment, the composition of the invention finds applications in cases wherein it is necessary to reduce or at any rate maintain unchanged the bacterial load present in a wound, and in certain cases wherein it is necessary to increase the rate of the natural process of regeneration and healing of the wound.
  • the composition of the invention finds applications in the sanitisation and regeneration of skin affected by sores and/or ulcers.
  • the composition of the invention finds applications in the treatment of decubital ulcers, infected ulcers, chronic ulcers.
  • the Applicant has, moreover, surprisingly discovered the existence of a direct linear correlation between the peroxide index PI expressed in equivalents of O 2 /kg of oil, or the amount of ozone absorbed by an oil during the ozonization reaction, and the density of the reaction mass.
  • the invention therefore extends to a method for determining the peroxide index PI (milli-equivalents of O 2 per kg of oil) of an ozonized oil by measuring the density, expressed in g/l, of the reaction mixture.
  • This method of analysis may be used as an alternative to the method reported in the Pharmacopoeia, which generally yields reliable responses only up to ozonide ion radical concentrations lower than those achievable in the present ozonization process.
  • the ozonized oils of the invention are subjected to a mean increase in oxygen, relative to a vegetable oil, for example, sunflower oil, from which is derived, of more than 7000 m-equivalents of O2 per kilogram of oil, typically up to approximately 5500 m-equivalents of O 2 per kilogram and advantageously up to 4000 m-equivalents of O 2 per kilogram of oil.
  • a vegetable oil for example, sunflower oil
  • the graph in Fig. 1 shows the peroxide index values, expressed as equivalents of O2 per kilogram of oil, on the Y-axis, and the values for the density of the mixture during the ozonization reaction, expressed as g/ml, on the X-axis.
  • the graph illustrated demonstrates the existence of a direct linear correlation between the two values.
  • Pure medical-grade oxygen is fed into a suitable 30-L generator at a flow rate of 140 L/h; an electrical charge of 6000 volts is applied to the generator, in this way ozone is formed, reaching a concentration of 90 mg/L of 0 3 .
  • the ozone is in turn bubbled into a suitable reactor containing sunflower oil.
  • the amount of ozone absorbed is monitored both by means of conventional titration, and by measuring the density of the reaction mixture.
  • An example correlation, applied in the process of industrial production of ozonized oil, is shown in Fig. 1.
  • composition 2a containing ozonized oil and alpha- bisabolol
  • formulation 2b containing ozonized oil as the only active principle, both formulated as a spray oil intended for treating cutaneous ulcers.
  • 2a A suitable reactor is charged with 67 parts of caprylic/capric acid triglycerides and 30 parts of ozonized oil. Following adequate mixing, 3 parts of a-bisabolol are added.
  • Preparations 2a and 2b were compared in the treatment of cutaneous ulcers of mean diameter approximately 2 cm. After 15 days, the ulcers treated with preparation 2a proved to have significantly smaller dimensions by comparison with the control, consisting of ulcers treated with preparation 2b. Moreover, the patients treated alternately and successively (crossover) with preparation 2a stated that they had obtained greater benefit, as compared with preparation 2b, due to the greater tolerability, the early sensation of increased sensitivity, and reduced pruritus and burning.
  • 3a 65.38 parts of water are placed in a smelting vessel and heated to 80°C. Simultaneously, a turboemulsifier is charged with 6 parts of C12-20 fatty acids esterified with polyethylene glycol(s) (PEG), 2.5 parts of C13-C15 alkanes, 3 parts of variously hydrogenated alkenes, 1.5 parts of cetyl alcohol, 2 parts of caprylic/capric acid triglycerides, 8 parts of other emulsifiers and conventional thickeners. The whole is heated, with stirring, to 80°C and the water, previously heated separately, is transferred to the emulsifier. The mass is emulsified until a homogenous and consistent mass is obtained.
  • PEG polyethylene glycol(s)
  • PEG polyethylene glycol(s)
  • 3 parts of variously hydrogenated alkenes 1.5 parts of cetyl alcohol
  • caprylic/capric acid triglycerides 8 parts of other emulsifiers and conventional thickeners
  • the evaluation of the bactericidal or bacteriostatic capacity of the products for comparison of pathogenic organisms was performed by applying the linear regression method in-vitro and calculating the % reduction (R%) in the viability of the microorganisms.
  • R% is defined by the ratio of the final and initial microorganism counts, multiplied by 100.
  • the microbiological analyses were performed at the University of Ferrara Department of Diagnostic and Experimental Medicine. Table 2a: Composition: ⁇ -bisabolol : ozonized oil in a ratio of 1 : 9
  • composition 1 part a-bisabolol - 9 parts ozonized oil showed a more elevated bactericidal activity than ozonized oil alone in comparisons of the microorganisms used: Streptococcus agalactae, Klebsiella pneumoniae and Pseudomonas aeruginosa.
  • Example 4 the synergistic effect of a-bisabolol and ozonized oil (of Table 1 ) in a ratio of 1 :15 was evaluated in respect of the antibacterial activity against the strains indicated above.
  • Table 3 shows the percentage survival of the inoculum concentrations over time and up to 24 h, as the effect of the ⁇ -bisabolol : ozonized oil composition in a ratio of 1 :15.
  • Table 3 Percentage survival of the concentrations of inoculum of composition 1 :15 ⁇ -bisabolol : ozonized oil (PI 4000)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un dispositif médical de désinfection ayant une activité topique améliorée dans le procédé de régénération d'ulcères et de blessures, et dans la résolution d'états inflammatoires. Cette composition comprend une quantité efficace d'une huile ozonisée et une quantité efficace d'une huile essentielle extraite de camomille. La présente invention concerne également les utilisations de ladite composition dans le secteur cosmétique et pharmaceutique. La composition de l'invention est spécialement utile dans la désinfection et la cicatrisation des lésions cutanées telles que les blessures, les abrasions, les ulcères aigus ou chroniques, et les plaies de différentes origines et de différentes natures.
PCT/IB2012/051057 2011-03-07 2012-03-07 Composition à base d'huile ozonisée destinée à une utilisation topique WO2012120454A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BR112013022891A BR112013022891A2 (pt) 2011-03-07 2012-03-07 composição para uso tópico à base de óleo ozonizado
EP12717849.9A EP2683356A1 (fr) 2011-03-07 2012-03-07 Composition à base d'huile ozonisée destinée à une utilisation topique
KR1020137026347A KR20140071956A (ko) 2011-03-07 2012-03-07 오존화 오일을 기본으로 하는 국소 사용을 위한 조성물
MA36296A MA35021B1 (fr) 2011-03-07 2012-03-07 Composition à base d'huile ozonisée destinée à une utilisation topique
MX2013010275A MX2013010275A (es) 2011-03-07 2012-03-07 Composicion para uso topico basada en aceite ozonizado.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000354A ITMI20110354A1 (it) 2011-03-07 2011-03-07 Composizione a base di olio ozonizzato per uso topico
ITMI2011A000354 2011-03-07

Publications (1)

Publication Number Publication Date
WO2012120454A1 true WO2012120454A1 (fr) 2012-09-13

Family

ID=43977024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/051057 WO2012120454A1 (fr) 2011-03-07 2012-03-07 Composition à base d'huile ozonisée destinée à une utilisation topique

Country Status (7)

Country Link
EP (1) EP2683356A1 (fr)
KR (1) KR20140071956A (fr)
BR (1) BR112013022891A2 (fr)
IT (1) ITMI20110354A1 (fr)
MA (1) MA35021B1 (fr)
MX (1) MX2013010275A (fr)
WO (1) WO2012120454A1 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013691A3 (fr) * 2013-07-26 2015-11-05 Paul O'malley Formulation de produit de soin buccal
WO2015170252A1 (fr) * 2014-05-07 2015-11-12 Multiossigen S.R.L. Produit d'activation des mécanismes de défense chez les plantes
WO2016036330A1 (fr) * 2014-09-02 2016-03-10 Tanyolac Deniz Couche de réparation tissulaire bioactive
ITUB20155024A1 (it) * 2015-11-24 2017-05-24 Dario Apuzzo Nuova composizione nutraceutica, somministrabile per via orale, per la prevenzione o trattamento di stati infiammatori e dolorifici delle vie aeree superiori.
IT201600111171A1 (it) * 2016-11-04 2018-05-04 Uras Cosmetics S R L S Kit per il trattamento della pelle e suo impiego
IT201800009621A1 (it) * 2018-10-19 2020-04-19 Roberto Soldati Composizione fitoterapica ozonizzata per la rigenerazione tissutale e ossea
WO2020084477A1 (fr) * 2018-10-22 2020-04-30 Giorgio Mezzoli Procédé de modification de l'odeur d'une huile ozonisée comprenant l'association de l'huile ozonisée avec certaines huiles essentielles et les compositions les contenant
EP3775120A4 (fr) * 2018-03-29 2021-06-02 Sabanci, Ahmet Ümit Solutions comprenant de l'huile ozonisée
EP3949980A1 (fr) * 2020-08-04 2022-02-09 Vassiliki Griva Compositions pour le traitement de la dermatite atopique contenant des huiles ozonisées et des agents antioxydants naturels

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1255660B (de) 1964-06-08 1967-12-07 Dr Klaus Gaebelein Verfahren zur Herstellung von Glykolaethergruppen enthaltenden Acetalperoxiden
US5183911A (en) 1986-03-01 1993-02-02 Dr. J. Hansler Gmbh Process for the production of stable ozonized oils from unsaturated vegetable oils
FR2784388A1 (fr) * 1998-10-07 2000-04-14 Bernard Sonnois Huile ozonisee obtenue par generateur alimente en oxygene pur - huile saturee en ozone
US20050113441A1 (en) 1999-11-25 2005-05-26 Moraleda Manuel-Antonia G. Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields
EP1626767A1 (fr) 2003-05-23 2006-02-22 Bioquell UK Limited Appareil et procede permettant de desinfecter une surface
WO2006021924A1 (fr) 2004-08-26 2006-03-02 Pieter Josua Le Roux Huile therapeutique
US20060074129A1 (en) 2002-04-08 2006-04-06 Mirabal Jesus M Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes
US20060153939A1 (en) * 2003-02-14 2006-07-13 Ordonez Jacome Neptali R C Method of obtaining and treating compounds from ozonized unsaturated vegetable oils for pharmaceutical compositions for medical and veterinary use
WO2007046122A2 (fr) * 2005-10-17 2007-04-26 Bioo3Pharma S.R.L. Huile ozonisee, procede d'elaboration et utilisation dans le domaine medical
GB2431581A (en) * 2005-10-27 2007-05-02 Steven Karim Ozonated oil formulations
US20070254963A1 (en) * 2004-04-20 2007-11-01 Haydee Stenti De Pirillo Ozonidzed Pharmaceutical Composition and Method
US20090291122A1 (en) 2006-06-01 2009-11-26 Sano Medical Bvba Wound Care Treatment Product
EP2149598A1 (fr) 2008-07-31 2010-02-03 Sanipan S.r.l. Procédé de fabrication d'un véhicule à base d'huile ozonée
EP2213165A1 (fr) * 2007-11-27 2010-08-04 Erc Technology Inc. Nouvelles compositions contenant un agent tensio-actif ozonisé

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008898C1 (ru) * 1992-08-26 1994-03-15 Геннадий Иванович Суколин Способ лечения грибковых и вирусных заболеваний кожи и/или ногтевых пластинок

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1255660B (de) 1964-06-08 1967-12-07 Dr Klaus Gaebelein Verfahren zur Herstellung von Glykolaethergruppen enthaltenden Acetalperoxiden
US5183911A (en) 1986-03-01 1993-02-02 Dr. J. Hansler Gmbh Process for the production of stable ozonized oils from unsaturated vegetable oils
FR2784388A1 (fr) * 1998-10-07 2000-04-14 Bernard Sonnois Huile ozonisee obtenue par generateur alimente en oxygene pur - huile saturee en ozone
US20050113441A1 (en) 1999-11-25 2005-05-26 Moraleda Manuel-Antonia G. Composition that comprises ozonised oils and/or other natural and/or synthetic ozonised products, and use thereof in pharmaceutical, cosmetic, dietary or food supplement products, in the human and veterinary fields
US20060074129A1 (en) 2002-04-08 2006-04-06 Mirabal Jesus M Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes
US20060153939A1 (en) * 2003-02-14 2006-07-13 Ordonez Jacome Neptali R C Method of obtaining and treating compounds from ozonized unsaturated vegetable oils for pharmaceutical compositions for medical and veterinary use
EP1626767A1 (fr) 2003-05-23 2006-02-22 Bioquell UK Limited Appareil et procede permettant de desinfecter une surface
US20070254963A1 (en) * 2004-04-20 2007-11-01 Haydee Stenti De Pirillo Ozonidzed Pharmaceutical Composition and Method
WO2006021924A1 (fr) 2004-08-26 2006-03-02 Pieter Josua Le Roux Huile therapeutique
WO2007046122A2 (fr) * 2005-10-17 2007-04-26 Bioo3Pharma S.R.L. Huile ozonisee, procede d'elaboration et utilisation dans le domaine medical
GB2431581A (en) * 2005-10-27 2007-05-02 Steven Karim Ozonated oil formulations
US20090291122A1 (en) 2006-06-01 2009-11-26 Sano Medical Bvba Wound Care Treatment Product
EP2213165A1 (fr) * 2007-11-27 2010-08-04 Erc Technology Inc. Nouvelles compositions contenant un agent tensio-actif ozonisé
EP2149598A1 (fr) 2008-07-31 2010-02-03 Sanipan S.r.l. Procédé de fabrication d'un véhicule à base d'huile ozonée

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HALLIWELL B., ANNU REV NUTR, vol. 16, 1996, pages 33 - 50
PRYOR ET AL., FREE RAD BIOL MED, vol. 19, 1995, pages 935 - 941
See also references of EP2683356A1
SINEGUB G A ET AL: "Treatment of fungal and viral diseases of skin and nails - by applying to affected areas ointment derived from vegetable oil ozonide(s) having peroxide number of 200-700", WPI WORLD PATENT INF, 26 August 1992 (1992-08-26), XP002941525 *
VELIO BOCCI, OZONE A NEW MEDICAL DRUG, SPRINGER, DORDRECHT, THE NETHERLANDS, 2005, pages 20
VELIO BOCCI, OZONE A NEW MEDICAL DRUG, SPRINGER, DORDRECHT, THE NETHERLANDS, 2005, pages 26

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013691A3 (fr) * 2013-07-26 2015-11-05 Paul O'malley Formulation de produit de soin buccal
WO2015170252A1 (fr) * 2014-05-07 2015-11-12 Multiossigen S.R.L. Produit d'activation des mécanismes de défense chez les plantes
WO2016036330A1 (fr) * 2014-09-02 2016-03-10 Tanyolac Deniz Couche de réparation tissulaire bioactive
ITUB20155024A1 (it) * 2015-11-24 2017-05-24 Dario Apuzzo Nuova composizione nutraceutica, somministrabile per via orale, per la prevenzione o trattamento di stati infiammatori e dolorifici delle vie aeree superiori.
IT201600111171A1 (it) * 2016-11-04 2018-05-04 Uras Cosmetics S R L S Kit per il trattamento della pelle e suo impiego
EP3775120A4 (fr) * 2018-03-29 2021-06-02 Sabanci, Ahmet Ümit Solutions comprenant de l'huile ozonisée
IT201800009621A1 (it) * 2018-10-19 2020-04-19 Roberto Soldati Composizione fitoterapica ozonizzata per la rigenerazione tissutale e ossea
WO2020079717A1 (fr) * 2018-10-19 2020-04-23 Soldati Roberto Composition phytothérapique ozonisée pour la régénération tissulaire et osseuse
WO2020084477A1 (fr) * 2018-10-22 2020-04-30 Giorgio Mezzoli Procédé de modification de l'odeur d'une huile ozonisée comprenant l'association de l'huile ozonisée avec certaines huiles essentielles et les compositions les contenant
EP3949980A1 (fr) * 2020-08-04 2022-02-09 Vassiliki Griva Compositions pour le traitement de la dermatite atopique contenant des huiles ozonisées et des agents antioxydants naturels

Also Published As

Publication number Publication date
MA35021B1 (fr) 2014-04-03
BR112013022891A2 (pt) 2016-08-16
KR20140071956A (ko) 2014-06-12
ITMI20110354A1 (it) 2012-09-08
MX2013010275A (es) 2014-03-31
EP2683356A1 (fr) 2014-01-15

Similar Documents

Publication Publication Date Title
EP2683356A1 (fr) Composition à base d'huile ozonisée destinée à une utilisation topique
JP3506701B2 (ja) 創傷治癒組成物，その調製方法と使用
JP2017226664A (ja) Ｄｇｌａ、１５−ｏｈｅｐａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法
KR20100016450A (ko) 피부 외용제 조성물
JP7313118B2 (ja) ザクロ種子油、ｒｏｓａ ｃａｎｉｎａ果実油、およびｉｎｕｌａ ｖｉｓｃｏｓａ含油樹脂または抽出物を含有する組成物
KR101018352B1 (ko) 봉독을 유효성분으로 하는 여드름 예방 및 치료용 조성물
WO1999059580A1 (fr) Agents preventifs/therapeutiques pour les affections cutanees
WO2008072941A1 (fr) Compositions contenant des composés d'origine naturelle pour une peau abîmée
CA2780025C (fr) Compositions dermatologiques renfermant un gras ou une huile d'un triglyceride d'acide gras essentiel
JP2015508094A (ja) Ｄｇｌａ、１５−ｏｈｅｐａ、及び／又は１５−ｈｅｔｒｅを含む医薬組成物並びにこれを使用する皮脂生成の低減法
WO2013014427A1 (fr) Compositions pour le traitement d'affections cutanées
EP3439676B1 (fr) Composition topique d'huile de poisson
EP4135730A1 (fr) Nouvelles compositions anhydres constituées d'huiles marines
WO2011119247A2 (fr) Composition topique de soin de la peau
WO2018084112A1 (fr) Agent antibactérien sélectif vis-à-vis de la souche responsable de l'acné
WO2013040721A1 (fr) Procédé et système pour la fabrication d'huiles naturelles ionisées et leur application dans le traitement chez l'homme, l'animal, ou dans les végétaux et en aquaculture
WO2016030609A1 (fr) Composition antimicrobienne
JP2024517225A (ja) 皮膚症状を治療するためのマヌカオイルおよびパルマローザオイルを含有する局所用組成物
EP3506876B1 (fr) Composition pour le traitement du champignon des ongles
IT201800009679A1 (it) Metodo per modificare l’odore dell’olio ozonizzato
EP4360616A1 (fr) Composition et procédé de traitement de lésions et/ou d'affections cutanées
WO2023049981A1 (fr) Composition anti-sébogène, formulation et utilisation de cette composition
BR102022019970A2 (pt) Composição antissebogênica, formulação e uso da composição
Shazadi Comparative analysis of antibacterial and antioxidant properties of transdermal preparations containing castor oil
WO2019178658A2 (fr) Composition cicatrisante, hydratante, humectante et émolliente pour une administration topique dans des lésions cutanées d'intertrigo, des lésions cutanées dues à l'incontinence urinaire et fécale et d'autres lésions associées

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12717849

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/010275

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1301004985

Country of ref document: TH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137026347

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012717849

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012717849

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013022891

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013022891

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130906